肝硬化患者的骨微结构与骨转换
这项单中心研究纳入32例新诊断肝硬化患者和32名健康对照,采用高分辨率外周定量CT评估骨微结构。结果显示桡骨和胫骨的骨小梁与骨皮质微结构均显著变差,且与疾病严重程度无关;双能X线吸收法测定的面积骨密度在各部位均降低,并与微结构参数相关。
要点
- 肝硬化患者桡骨骨小梁骨体积分数较对照低17%(校正p=0.028),胫骨低19%(p=0.024)。
- 胫骨骨皮质骨密度低7%(p=0.007)、骨皮质厚度低28%(p=0.001)、骨皮质孔隙率高32%(p=0.023)。
- 面积骨密度在腰椎低13%、全髋低11%、全身低9%、桡骨低17%、跟骨低26%,且与微结构参数相关。
核心结论
- 肝硬化会同时损害骨小梁和骨皮质微结构,且与疾病严重程度无关。
- 面积骨密度在所有评估部位均降低,提示全身性受累。
- 作者认为,无论肝硬化病因或疾病严重程度如何,面积骨密度测量都是骨科筛查的合适工具。
研究设计与样本
- 单中心研究,纳入近期诊断的肝硬化患者32例和对照32名。
- 确定肝硬化类型后,采用高分辨率外周定量CT评估骨微结构参数。
主要发现
- 桡骨骨小梁骨体积分数较对照低17%(校正p=0.028),胫骨低19%(p=0.024)。
- 胫骨骨皮质骨密度较对照低7%(p=0.007),骨皮质厚度低28%(p=0.001),骨皮质孔隙率高32%(p=0.023)。
- 面积骨密度较对照在腰椎低13%、全髋低11%、全身低9%、桡骨低17%、跟骨低26%。
- 疾病严重程度与微结构之间无相关性。
- 双能X线吸收法测定的面积骨密度与骨皮质和骨小梁微结构参数相关性良好。
临床怎么用
- 作者认为,肝硬化患者无论病因或疾病严重程度如何,面积骨密度测量都是骨科筛查的合适工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Liver cirrhosis leads to bone loss. To date, information on bone quality (three-dimensional microarchitecture) and, thus, bone strength is scarce. We observed decreased bone quality at both assessed sites, independent of disease severity. Therefore, all patients should undergo early-stage screening for osteoporosis. INTRODUCTION: Recent studies found low bone mineral density in cirrhosis, but data on bone microstructure are scarce. This study assessed weight-bearing and non-weight-bearing bones in patients with cirrhosis and healthy controls. The primary objective was to evaluate trabecular and cortical microarchitecture. METHODS: This was a single-center study in patients with recently diagnosed hepatic cirrhosis. Thirty-two patients and 32 controls participated in this study. After determining the type of cirrhosis, the parameters of bone microarchitecture were assessed by high-resolution peripheral quantitative computed tomography. RESULTS: Both cortical and trabecular microarchitectures showed significant alterations. At the radius, trabecular bone volume fraction was 17% lower (corrected p = 0.028), and, at the tibia, differences were slightly more pronounced. Trabecular bone volume fraction was 19% lower (p = 0.024), cortical bone mineral density 7% (p = 0.007), and cortical thickness 28% (p = 0.001), while cortical porosity was 32% higher (p = 0.023), compared to controls. Areal bone mineral density was lower (lumbar spine - 13%, total hip - 11%, total body - 9%, radius - 17%, and calcaneus - 26%). There was no correlation between disease severity and microarchitecture. Areal bone mineral density (aBMD) measured by dual-energy X-ray absorptiometry (DXA) correlated well with parameters of cortical and trabecular microarchitecture. CONCLUSIONS: Hepatic cirrhosis deteriorates both trabecular and cortical microarchitecture, regardless of disease severity. Areal bone mineral density is diminished at all sites as a sign of generalized affection. In patients with hepatic cirrhosis, regardless of its origin or disease severity, aBMD measurements are an appropriate tool for osteologic screening.
引用
- Wakolbinger R, Muschitz C, Scheriau G, et al. Bone microarchitecture and bone turnover in hepatic cirrhosis. Osteoporos Int. 2019. PMID: 30788527. doi:10.1007/s00198-019-04870-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。